Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|July 2, 2021
Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant CellsDanda Chapagai, Gurusankar Ramamoorthy, Jessy Varghese, et al.
Biophysical Chemistry|October 27, 2009
New insights into DNA-binding behavior of Wilms tumor protein (WT1)--a dual studyElmar Nurmemmedov, Raymond K Yengo, Hüseyin Uysal, et al.
Human Antibodies|September 19, 2018
Antibody drug conjugates: Progress, pitfalls, and promisesAnubhab Mukherjee, Ariana K Waters, Ivan Babic, et al.
Journal of Translational Medicine|October 20, 2017
A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in gliomaVenkata Yenugonda, Natsuko Nomura, Valentina Kouznetsova, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
Increased interaction between connexin43 and microtubules is critical for glioblastoma stem-like cell maintenance and tumorigenicityJames W Smyth, Sujuan Guo, Lorie O'Rourke, et al.
Human Antibodies|October 18, 2017
Pritumumab, the first therapeutic antibody for glioma patientsIvan Babic, Elmar Nurmemmedov, Venkata M Yenugonda, et al.
European Journal of Medicinal Chemistry|November 4, 2021
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACESandra N Craig, Merissa Baxter, Danda Chapagai, et al.
Oncotarget|November 16, 2020
Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesisMyoung Sook Kim, Ramkishore Gernapudi, Yessenia Cedeño Cedeño, et al.
Pageof 4